Showing results (411-420 of 1,877) with videos related to
Sort By:
Pageof 188
Immunotherapy|March 5, 2024
A rare case of daratumumab-associated encephalopathy in multiple myelomaJingjing Xiang, Zirui Hong, Yu Zhang, et al.Immunotherapy|February 16, 2024
Treatment and prognostic implications of strong PD-L1 expression in primary hepatic sarcomatoid carcinomaSubathra Radhakrishnan, Catherine Ann Martin, Mukul Vij, et al.Immunotherapy|February 16, 2024
Facilitated subcutaneous immunoglobulin treatment patterns in pediatric patients with primary immunodeficiency diseasesMonika Mach-Tomalska, Anna Pituch-Noworolska, Ewa Bień, et al.Immunotherapy|March 26, 2024
Sintilimab-induced severe erosive hemorrhagic gastritis and pyloric obstruction: a case report and literature reviewWenfang Xiong, Zhenzhen Yang, Youxiang ChenImmunotherapy|July 3, 2024
A novel dose-adjustment protocol for interrupted subcutaneous immunotherapy in children with allergic rhinitisMin Pan, Jianrong XueImmunotherapy|July 17, 2024
Impact of low sodium values on survival outcomes of patients with cancer receiving immune checkpoint inhibitorsBeliz Bahar Karaoğlan, Emre Yekedüz, Satı Coşkun Yazgan, et al.Immunotherapy|March 26, 2024
Certolizumab pegol in the treatment of axial spondyloarthritisElizabeth Anderson, Secia Beier, Julianna DesmaraisImmunotherapy|January 25, 2024
Two studies to learn if avacincaptad pegol works and is safe in people with geographic atrophy: a plain language summary of the GATHER1 and GATHER 2 studiesGlenn J Jaffe, Arshad M KhananiImmunotherapy|January 30, 2024
Evaluating the effectiveness of the Charlson Comorbidity Index in predicting immune checkpoint inhibitor-related adverse eventsİlknur Deliktaş Onur, Emel Mutlu, Elif Sertesen, et al.Immunotherapy|January 12, 2024
Pathological findings directing immunotherapy in renal cell carcinomasFadime Eda Gökalp Satıcı, Yasemin Yuyucu KarabulutPageof 188